Skip to main content
Download PDF

Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs

BMC Cancer volume 24, Article number: 1053 (2024) Cite this article

Abstract

Purpose

The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long-term overall survival(OS)and provide a theoretical basis for further clinical research.

Patients and methods

In total, 238 patients with EGFR-TKIs and OS ≥ 12 months were statistically analysed. Patients were grouped: the D group without primary tumor radiotherapy and the R group with it.The R group were divided into three groups according to the interval between the start of EGFR-TKIs and the start of primary tumor radiotherapy: R0 − 30(<30 days), R30 − PD(≥ 30 days and disease stable), and RPD(radiotherapy after disease progression). The Kaplan-Meier method and log-rank test were used for survival analyses. Exploratory landmark analyses were investigated.

Results

The OS rates at 1, 2, 3, 5 years for the R group and D group were 96.8%, 62.9%, 38.3%, 17.1%, and 95.6%, 37.7%, 21.8%, 2.9%, respectively; the corresponding MST was 29 months(95% CI: 24.3–33.7) for the R group and 22 months(95% CI: 20.4–23.6) for the D group (χ2 = 13.480, p<0.001). Multivariate analysis revealed that primary tumor radiotherapy was independent predictors of prolonged OS.Among the four groups, The R30 − PD appeared to have the best OS (D, χ2 = 19.307, p<0.001;R0 − 30, χ2 = 11.687, p = 0.01; RPD, χ2 = 4.086, p = 0.043). Landmark analyses(22 months) showed the R30 − PD group had a significant long-term OS.The incidence of radiation pneumonitis ≥ grade 2 was17.3%(n = 19)and radiation esophagitis ≥ grade 2 was observed in 32 patients(29.1%).

Conclusions

Our results showed that primary tumour radiotherapy may prolong long-term OS with acceptable toxicities. Appropriate delay(R30 − PD)of primary tumour radiotherapy may be the best choice.Premature radiotherapy(R0 − 30) and radiotherapy after disease progression (RPD)may not be reasonable for long-term OS.

Peer Review reports

Introduction

Non-small cell lung cancer (NSCLC) accounted for 86% of newly diagnosed lung cancer, and approximately 60% of them had metastatic lesion in initial diagnosis [1].For such patients, Systemic treatment is the mainstay of treatment and has entered the era of precision medicine according to result of Genetic testing [2, 3]. Epidermal growth factor receptor (EGFR) mutation is the most common gene mutation, especially in Asian population [4]. EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs) has become the first-line treatment for metastatic NSCLC due to better objective response rates (ORR)and progression-free survival (PFS) compared with systemic chemotherapy [5,6,7,8].

However, the fatal drawback of EGFR-TKIs is the inevitable disease progression because of drug resistance [9, 10]. Tumor progression mainly occurred in the original disease sites, and this failure pattern suggested that radiotherapy may delay disease progression and prolong overall survival(OS) [11, 12]. Numerous studies have confirmed that primary tumor radiotherapy can significantly prolong progression-free survival (PFS)and OS on the basis of EGFR-TKIs [13,14,15,16,17,18]. Unlike traditional chemotherapy, EGFR-TKIs is a long-term treatment that is continued by oral administration until extensive disease progression [2, 3]. In the interim, when is radiation therapy most appropriate? Experts have explored and researched it, but it is only limited to theoretical analysis [19, 20]. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long-term OS, and to provide a theoretical basis for further clinical research.

Materials and methods

Patients

Our research subjects were patients with NSCLC who had EGFR-mutation(EGFR-M) from January 2014 to December 2021 at Affiliated Cancer Hospital of Guizhou Medical University (the 7th edition of the American Joint Committee on Cancer staging system).We hunted out potential cases in the electronic medical record system.Keywords included Gefitinib, Icotinib, Erlotinib, Osimertinib and Almonertinib, which were available EGFR-TKIs in our hospital. These patients who met the following criteria were enrolled: (1) histologically or cytologically confirmed NSCLC and molecular testing confirmed EGFR-M (2) EGFR-TKIs as first line therapy; (3) ≥ 18 years old (4) no previous thoracic radiotherapy or surgery; (5) no previous malignancy or other concomitant malignant diseases; (6) OS ≥ 12 months [21,22,23,24].

We collected data from the electronic medical records and the department of epidemiology, including age at initial diagnosis, sex, smoking status, histology, TNM stage, EGFR-M types, metastasis status, radiotherapy data, and so on. This study was approved by the ethics committee of the affiliated cancer Hospital of Guizhou medical university.

According to primary tumor radiotherapy, patients were grouped: the D group without primary tumor radiotherapy (primary tumor, lymph nodes) and the R group with it.The R group were divided into three groups: R0 − 30 group with the interval between the start of EGFR-TKIs and the start of radiotherapy<30 days, R30 − PD group with that ≥ 30 days and without disease progression, RPD group with primary tumor radiotherapy after disease progression.The start of radiotherapy was defined as the time of Simulation Computed Tomography Scan(SCTS) in order to perform primary tumor radiotherapy.

Radiotherapy

Primary tumor radiotherapy

Primary tumor radiotherapy was not mandatory for any patient, but it was performed when patient had signed an informed consent form. The treating radiotherapist made the radiotherapy regime. The plans were evaluated as 100% of the prescription dose line including 100% of the GTV and 90% of the prescription dose including 98% of the PTV. The percentage of total lung volume receiving ≥ 20 Gy (V20) was kept to ≤ 32%, the maximum point dose to the spinal cord was ≤ 50 Gy, the mean oesophageal dose was ≤ 35 Gy, and the mean heart dose was ≤ 30 Gy for all individual treatment plans. The prescribed dose was to be at least 30 Gy and given according to the tolerance of the organ at risk. One hundred and twenty-four patients received external beam radiation therapy for primary tumor(30 Gy ≤ dose ≤ 54 Gy, n = 34;dose>54 Gy, n = 90). Radiotherapy toxicities were recorded and graded according to Common Terminology Criteria for Adverse Events (CTCAE, version4.0).

Metastases radiotherapy

Radiotherapy for metastatic lesions should meet two conditions at the same time.First, patient suffered from brain metastasis or bone metastasis with cancer pain or risk of fracture, and so on. Second, patient had signed an informed consent form. Brain metastases radiotherapy included whole brain radiotherapy (WBRT) (30 Gy/10 fractions or 40 Gy/20 fractions), simultaneous integrated boost of intensity modulated radiation therapy(SIB-IMRT)(Boost, 47–48 Gy/10–12 fractions, WBRT 30 Gy/10–12 fractions), and fractionated stereotactic radiotherapy (FSRT) (50 Gy/10fractions). Bone metastases radiotherapy was given in 3 Gy per fraction, 5 days per week, to a total dose of 30–45 Gy.

Statistical analysis

The study employed SPSS software (version 26.0) for statistical analysis. Dichotomous variables were presented as counts and analyzed using Pearson’s chi-square or Fisher’s exact test. Overall survival(OS) [25] was defined as the period from the date of treatment commencement to the last follow-up date or death from any cause.The Kaplan-Meier method and log-rank test were used for survival analyses. Using the Cox proportional hazards model, the hazard ratio (HR) and 95% confidence intervals (CIs) were calculated. To investigate the impact of radiation time on long-term survival, landmark analysis of OS was performed.Because the MST for patients with stage IV NSCLC who receive first-generation EGFR-TKIs was approximately 22 months [21,22,23,24], we chose 22 months from the start of treatment as the time point for landmark analyses.All statistical tests were 2-sided, and P values < 0.05 were considered statistically significant.

Results

Patient characteristics

In total, 238 patients with EGFR-TKIs and OS ≥ 12 months were statistically analysed, including 114 cases in the D group and 124 in the R group (R0 − 30 group, n = 44;R30 − PD group, n = 47; RPD group, n = 33; Figure 1). The patient characteristics are presented in Table 1. The majority of patients had histology of adenocarcinoma(n = 223, 93.7%)and stage IVB (n = 183,76.9%) and non-oligometastases (n = 165, 69.3%).The ratio of males to females was 0.725; the median age was 59 years (28–84 years, age ≤ 60 years in 128 patients). The T and N stages were as follows: 37 cases with T1 − 2N0 − 2, 40 with T1 − 2N3, 56 with T3 − 4N0 − 2, and 105 with T3 − 4N3. The common site of metastatic disease at initial diagnosis was the bone (57.6%), lung (37.0%), and brain (34.5%).Most patients (n = 155,65.1%)underwent simple EGFR-TKIs during the course of the disease. There was no significant difference between the three groups with respect to gender, age, histology, smoking status, EGFR mutation type, metastases number, the types of EGFK-TKIs, and.

subsequent treatment.

Fig. 1
figure 1

Flowchart of patient cohort. HIV: human immunodificiency virus; NSCLC: Non-small cell lung cancer; EGFR-M: Epidermal growth factor receptor mutation; TKIs: Tyrosine kinase inhibitors.The start of radiotherapy; the time of Simulation Computed Tomography Scan in order to perform primary tumor radiotherapy

Full size image
Table 1 Patient characteristics
Full size table

Radiotherapy

Of the 238 patients, 38.2% (91 patients) received pre-radiotherapy of primary tumour, 13.9%(33 patients)following disease progression, and 47.9% (114 patients) did not receive primary tumor radiotherapy (Table 1). Of the 91 patients with pre-radiotherapy of primary tumour, 49.5% (n = 44) received it within 30 days after EGFR-TKIs, 50.5% (n = 47) received it beyond 30 days after EGFR-TKIs and without disease progression. One hundred and twenty-five patients underwent metastases radiotherapy, including 29 in the D group, 35 in the R0 − 30 group, 36 in the R30 − PD group, and 25 in the RPD group.

The median interval between the start of EGFR-TKIs and the start of radiotherapy was 32 days(range 0-281 days). The median interval between the SCTS and the execution of radiotherapy was 7 days.

Survival outcomes and OS analysis

The final follow-up was in July 2023, with a median follow-up of 23.3 months (range 12–74.3 months). At the last follow-up visit, 61 of 238 patients were still alive. The median survival time(MST) for all patients was 24.2 months (95% CI: 22.6–25.8), and the OS rates were 96.2% at 1 year, 50.3% at 2 years, 30.0% at 3 years, and 10.7% at 5 years. The OS rates at 1, 2, 3, 5 years for the R group and D group were 96.8%, 62.9%, 38.3%, 17.1%, and 95.6%, 37.7%, 21.8%, 2.9%, respectively; the corresponding MST was 29 months (95% CI: 24.3–33.7) for the R group and 22 months(95% CI: 20.4–23.6) for the D group (χ2 = 13.480, p<0.001) (Fig. 2). Univariate analysis results are shown in Table 2.Multivariate analysis revealed that primary tumor radiotherapy, Stage IVA, Adenocarcinoma, Oligometastasis, and Third generation EGFR-TKIs were independent predictors of prolonged OS(Table 3).

Fig. 2
figure 2

Overall survival for Group R and D group

Full size image
Fig. 3
figure 3

Overall survival for Group R0 − 30, R30 − PD,RPD and D

Full size image
Table 2 Univariable Analysis of Overall Survival
Full size table
Table 3 Multivariate analysis of overall survival
Full size table

Landmark survival analyses

Among the four groups, The R30 − PD appeared to have the best OS (D group, χ2 = 19.307, p<0.001;R0 − 30 group, χ2 = 11.687, p = 0.01; RPD group, χ2 = 4.086, p = 0.043; Figure3; Supplement Table 1 ).In the landmark analysis using 22 months time point, patients in the group R30 −  PD had the most excellent long-term survival (D group, χ2 = 14.254, p<0.001; R0 − 30 group, χ2 = 12.414, p<0.001; RPD group, χ2 = 8.897, p = 0.003; Supplement Table 2; Fig. 1 ).

Radiation toxicity

The majority of lung radiation toxicities were grade 1. According to our observation, patients did not exhibit Grade 4–5 radiation toxicities. In 110 evaluable patients, there were 19 (17.3%) and 32 (29.1%) cases of grade ≥ 2 radiation pneumonitis and esophagitis, respectively.

Discussion

Stage IV non-small cell lung cancer accounts for more than half of all cases [26]. Both National Comprehensive Cancer Network(NCCN)and European Society for Medical Oncology (ESMO) guidelines recommend systemic therapy as the cornerstone of comprehensive treatment according to result of Genetic testing [2, 3]. EGFR positive mutations are the most common mutation type for non-small cell lung cancer.The first-line treatment of Stage IV non-small cell lung cancer with EGFR positive mutations is undoubtedly EGFR-TKIs, due to better ORR and PFS, but ultimately it did not bring better overall survival [27, 28]. The main limiting factor is acquired drug resistance [15]. Studies have found that the most common failure of EGFR-TKIs is in the initial involved lesions, especially in the primary tumor [11, 12]. This failure pattern suggested the necessity of local radiotherapy intervention, which can not only improve local control [15, 29] but may also reduce the systemic reseeding of distant metastasis [11]. A number of studies have suggested that primary tumor radiotherapy before disease progression can significantly prolong PFS and OS [13,14,15,16,17,18, 30]. Radiotherapy also confered a survival benefit for non-small cell lung cancer with oligoprogression [18, 31, 32]. Our study also showed that the primary tumor radiotherapy significantly prolonged overall survival, as compared with such patients treated with EGFR-TKIs alone.

The overall survival of concurrent chemoradiotherapy was significantly better than sequential chemoradiotherapy for locally advanced non-small cell lung cancer [33]. Similar results have been obtained in studies related to Stage IV non-small cell lung cancer [34, 35]. However, compared with traditional systemic chemotherapy, EGFR-TKIs has no limit on the number of cycles and needs to be taken orally at all times. Radiotherapy performance before disease progression should always be a reasonable choice. A Study [36] performed byYen YC, et al. showed that the time between TKI initiation and thoracic RT initiation was not uniform, 1–3 months in 29 patients(9.83%),4–6 months in 127 patients (43.05%), 9–12 months in 109 patients (36.95),and 10-12months in 30 patients (10.17%). Tang Y et al [19] suggested that local therapy can be adopted after two months after TKI initiation due to considerable shrinkage for TKI therapy. A radiotherapy timing analysis [20] based on tumour volume change recommended that the 40th day after targeted therapy may be a reasonable time to start radiotherapy for stage IV NSCLC with EGFR-positive mutations. Our study showed that patients receiving primary tumor radiotherapy from 30 days after EGFR-TKIs to pre-progression had better long-term OS than those with primary tumor radiotherapy within 30 days. The median interval between the SCTS and the execution of radiotherapy was 7 days.The data of our study showed that the majority of patients (n = 201,84.5%) had stage T3 − 4 and/or N2 − 3, which was similar to the data of previous studies [37,38,39]. Due to the relatively large gross tumour volume, premature radiotherapy may fail to achieve the radical radiation dose, so as to prolong OS. The incidence of radiation toxicities in EGFR-TKIs combined with radiotherapy was relatively common [25, 40,41,42]. If the radiation dose is increased blindly, it may lead to severe heart and lung injury, which may affect the quality of life and even endanger the life [20, 43]. Targeted therapy has a high ORR, and the primary tumor volume gradually shrinked after EGFR-TKIs to achieve the purpose of low damage and high radiation dose [19, 20]. Therefore, appropriate delay of primary tumour radiotherapy may be a better choice and premature radiotherapy may not be reasonable.

Acquired resistance is an inevitable defect of EGFR-TKIs. Studies showed that radiotherapy can prolong overall survival for patients with oligoprogressive disease in EGFR-mutated non-small cell lung cancer [18, 31, 32]. Our study suggested that primary tumor radiotherapy after disease progression(RPD) similarly prolonged overall survival, but appeared to be detrimental to long-term OS compared with R30 − PD. Acquired resistance means that radiotherapy may miss the best opportunity to kill potential metastatic tumor cells [11, 44]. At this time, more metastatic lesions may occur except for that detected by systemic imaging due to the sensitivity and specificity of current examination. The volume of primary tumors increases after disease progression, and low damage and radical radiotherapy dose may not be achieved [20]for such patients. Previous studies of concurrent chemoradiotherapy in stage IV NSCLC have suggested that radiotherapy may have a greater survival benefit on the basis of chemotherapy effectivity [45, 46].Therefore, similar benefits may have been limited to EGFR-TKIs resistance.Some studies have confirmed the enhanced anti-tumor activity of EGFR-TKIs [47,48,49], and radiotherapy reduces EGFR-TKIs acquired resistance [50, 51]. However, whether these mechanisms between radiotherapy and EGFR-TKIs still exist is not clear while acquired resistance occurs. There may be many other unknown factors affecting this result, which need to be further explored.

In order to achieve high-quality long-term OS, the radiation toxicity is one of the focuses that must be paid attention to. A number of previous studies [25, 40,41,42,43]have showed that most of toxicity are grade 1–2 for NSCLC with comprehensive treatment of EGFR-TKIs and primary tumors radiotherapy and special attention should be paid to the occurrence of fatal radiation pneumonitis(RP).Our study showed the incidence of RP ≥ grade 2 was17.3% (n = 19) and radiation esophagitis ≥ grade 2 was observed in 32 patients (29.1%). There were no fatal toxicity in our study.

Although the results of our study are very interesting and may have clinical implications for the appropriate timing of primary tumors radiotherapy, there are several limitations. First of all, the sample included only hospitalized patients, which may lead to selection bias. Second of all, the advantage of this research was a population of our hospitalized patients, single institution study is a non-negligible disadvantage. Third of all, the majority of patients received only first generation EGFR-TKIs(n = 130,54.6%)and did not receive systemic chemotherapy (n = 155,65.1%). Finally, this was a retrospective study with inevitable bias. Therefore, randomized controlled trials are necessary to validate the findings of this study.

Conclusions

Our results showed that primary tumour radiotherapy may prolong long-term OS with acceptable toxicities. Appropriate delay(R30 − PD)of primary tumour radiotherapy may be the best choice.Premature radiotherapy(R0 − 30) and radiotherapy after disease progression (RPD) may not be reasonable for long-term OS. Potential biases should not be neglected: further randomized controlled trials are necessary to confirm this result.

Data availability

No datasets were generated or analysed during the current study.

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

    Article  PubMed  Google Scholar 

  2. Ettinger DS, Wood DE, Aisner DL, et al. Non-small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(5):497–530.

    Article  PubMed  Google Scholar 

  3. Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33(5):466–87.

    Article  PubMed  CAS  Google Scholar 

  4. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–62.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.

    Article  PubMed  CAS  Google Scholar 

  6. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.

    Article  PubMed  CAS  Google Scholar 

  7. Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017;28(10):2443–50.

    Article  PubMed  CAS  Google Scholar 

  8. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-Mutated Advanced Non-small-cell Lung Cancer. N Engl J Med. 2018;378(2):113–25.

    Article  PubMed  CAS  Google Scholar 

  9. Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl1):i10–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Tripathi SK, Pandey K, Rengasamy K, Biswal BK. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. Med Res Rev. 2020;40(6):2132–76.

    Article  PubMed  CAS  Google Scholar 

  11. Al-Halabi H, Sayegh K, Digamurthy SR, et al. Pattern of failure analysis in metastatic EGFR-Mutant Lung Cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body Radiation Therapy. J Thorac Oncol. 2015;10(11):1601–7.

    Article  PubMed  CAS  Google Scholar 

  12. Patel SH, Rimner A, Foster A, et al. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer. 2017;108:109–14.

    Article  PubMed  Google Scholar 

  13. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Petrelli F, Ghidini A, Cabiddu M, et al. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: a systematic review and meta-analysis. Lung Cancer. 2018;126:194–200.

    Article  PubMed  Google Scholar 

  17. Arrieta O, Barrón F, Maldonado F, et al. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: a phase II study. Lung Cancer. 2019;130:67–75.

    Article  PubMed  Google Scholar 

  18. Hu C, Wu S, Deng R, et al. Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: a real-world study. Cancer Med. 2023;12(1):266–73.

    Article  PubMed  CAS  Google Scholar 

  19. Tang Y, Xia B, Xu X, et al. Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI. Lung Cancer. 2019;140:65–70.

    Article  PubMed  Google Scholar 

  20. Li Q, Liang N, Zhang X, et al. Reasonable timing of Radiotherapy for Stage IV Non-small-cell Lung Cancer during targeted therapy based on Tumour volume change. Front Oncol. 2021;11:705303.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.

    Article  PubMed  CAS  Google Scholar 

  22. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.

    Article  PubMed  CAS  Google Scholar 

  23. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

    Article  PubMed  CAS  Google Scholar 

  24. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–9.

    Article  PubMed  Google Scholar 

  25. Chang CC, Chi KH, Kao SJ, et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer. 2011;73(2):189–94.

    Article  PubMed  Google Scholar 

  26. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.

    PubMed  PubMed Central  Google Scholar 

  27. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–74.

    Article  PubMed  CAS  Google Scholar 

  28. Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus Gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Zheng L, Wang Y, Xu Z et al. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations. Oncologist. 2019.

  30. Wang X, Zeng Z, Cai J, et al. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study. BMC Cancer. 2021;21(1):482.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Rossi S, Finocchiaro G, Noia VD, et al. Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncol. 2019;15(33):3775–82.

    Article  PubMed  CAS  Google Scholar 

  32. Chan O, Lee V, Mok T, Mo F, Chang A, Yeung R. The role of Radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis. Clin Oncol (R Coll Radiol). 2017;29(9):568–75.

    Article  PubMed  CAS  Google Scholar 

  33. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Lopez Guerra JL, Gomez D, Zhuang Y, et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012;84(1):e61–7.

    Article  PubMed  Google Scholar 

  35. Su S, Li T, Lu B, et al. Three-Dimensional Radiation Therapy to the primary tumor with concurrent chemotherapy in patients with stage IV Non-small Cell Lung Cancer: results of a Multicenter phase 2 study from PPRA-RTOG, China. Int J Radiat Oncol Biol Phys. 2015;93(4):769–77.

    Article  PubMed  Google Scholar 

  36. Yen YC, Hsu HL, Chang JH, et al. Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment. Radiother Oncol. 2018;129(1):52–60.

    Article  PubMed  Google Scholar 

  37. Li Q, Hu C, Su S, et al. Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy. Front Oncol. 2023;13:974735.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hu X, Li H, Kang X, et al. First-line tyrosine kinase inhibitors combined with local consolidative Radiation Therapy for Elderly patients with Oligometastatic Non-small Cell Lung Cancer Harboring EGFR activating mutations. Front Oncol. 2022;12:766066.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Hu F, Xu J, Zhang B, et al. Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20(1):e81–90.

    Article  PubMed  Google Scholar 

  40. Zhuang H, Hou H, Yuan Z, et al. Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy. Onco Targets Ther. 2014;7:807–13.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Zhuang H, Yuan Z, Chang JY, et al. Radiation pneumonitis in patients with non–small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol. 2014;9(6):882–5.

    Article  PubMed  CAS  Google Scholar 

  42. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006;66(5):1399–407.

    Article  PubMed  CAS  Google Scholar 

  43. Qin H, Ke J, Dong S, et al. Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations. BMC Cancer. 2022;22(1):1012.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20(15):3199–205.

    Article  PubMed  Google Scholar 

  45. Ouyang WW, Su SF, Hu YX, et al. Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study. BMC Cancer. 2014;14:491.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Su S, Hu Y, Ouyang W, et al. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic stage IV non-small cell lung cancer? Secondary analysis of two prospective studies. BMC Cancer. 2016;16(1):908.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59(8):1935–40.

    PubMed  CAS  Google Scholar 

  48. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

    Article  PubMed  CAS  Google Scholar 

  49. Sartor CI. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol. 2003;13(1):22–30.

    Article  PubMed  Google Scholar 

  50. Shintani S, Li C, Mihara M, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer. 2003;107(6):1030–7.

    Article  PubMed  CAS  Google Scholar 

  51. Tsai YC, Ho PY, Tzen KY, et al. Synergistic blockade of EGFR and HER2 by New-Generation EGFR tyrosine kinase inhibitor enhances Radiation Effect in bladder Cancer cells. Mol Cancer Ther. 2015;14(3):810–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Huiqin Li at Affiliated Cancer Hospital of Guizhou Medical University, China, for her work following up with all patients.

Funding

Guizhou Science and Technology Plan Support Project [Qiankehe support (2019) 2795].

Author information

Authors and Affiliations

  1. Department of Thoracic Oncology, Affiliated Hospital of Guizhou Medical University, 1 Beijing Road West, Guiyang, 550004, China

    Qingsong Li, Na Liang, Weiwei Ouyang, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li & Bing Lu

  2. Department of Thoracic Oncology, Affiliated Cancer Hospital of Guizhou Medical University, 1 Beijing Road West, Guiyang, 550004, China

    Qingsong Li, Na Liang, Weiwei Ouyang, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li & Bing Lu

  3. Teaching and Research Department of Oncology, Clinical Medical College of Guizhou Medical University, 1 Beijing Road West, Guiyang, 550004, China

    Qingsong Li, Na Liang, Weiwei Ouyang, Shengfa Su, Yichao Geng, Yinxiang Hu & Bing Lu

Authors
  1. Qingsong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Na Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weiwei Ouyang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shengfa Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhu Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yichao Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yinxiang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Huiqin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bing Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LQS participated in the case collection, drafting, and wrote the manuscript.OYWW made useful comments and participated in revising the manuscript.LB designed the study and performed the statistical analysis.LN participated in the analysis and interpretation of the data, as well as in drafting and revising all versions of the manuscript. All authors have read and approved the final version for publication.

Corresponding author

Correspondence to Bing Lu.

Ethics declarations

Ethical approval

This study was reviewed by the ethical review boards in China (Ethics Committee of Affiliated Cancer Hospital of Guizhou Medical University, GuiYang, China).

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Supplementary Material 3

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Q., Liang, N., Ouyang, W. et al. Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs. BMC Cancer 24, 1053 (2024). https://doi.org/10.1186/s12885-024-12826-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-024-12826-1

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us